Candel Therapeutics' CAN-2409 delivers durable benefit in positive phase 3 prostate cancer trial

By Proactive Investors / October 02, 2025 / www.youtube.com / Article Link

Candel Therapeutics CEO Dr. Paul Peter Tak joined Steve Darling from Proactive to highlight new subgroup analyses from the ...

Recent News

Gold stocks still up after pullback late in the week

October 20, 2025 / www.canadianminingreport.com

US regional bank slump goes global, driving market into gold

October 20, 2025 / www.canadianminingreport.com

Gold stocks weaker but outperform slump in other sectors

October 13, 2025 / www.canadianminingreport.com

West Africa-focussed Robex and PDI to merge

October 13, 2025 / www.canadianminingreport.com

Gold stocks outperform equity market gains

October 06, 2025 / www.canadianminingreport.com

See all >